Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy.
OBJECTIVE
To report our initial experience of limited macular translocation in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration following photodynamic therapy with verteporfin.


METHODS
Interventional case series.


METHODS
Retrospective review of four eyes of four consecutive patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who underwent effective limited macular translocation following photodynamic therapy. The mean logarithm of minimal angle of resolution preoperative best-corrected visual acuity was 20/190 (range, 20/150 to 20/200), and in all eyes the visual acuity was 20/150 or worse. The major outcome measures were postoperative visual acuity and complications related to the surgery.


RESULTS
The mean postoperative follow-up was 6.75 months (range, 6-8 months). Postoperative best-corrected visual acuity improved by 2 or more Snellen lines of visual acuity in three of four eyes (75%) and remained within 1 line in one of four eyes (25%). The mean postoperative best-corrected visual acuity was 20/100 (range, 20/40 to 20/150), and in two of the four eyes (50%) the visual acuity achieved was 20/100 or better. No complication was observed.


CONCLUSIONS
Limited macular translocation may be a viable option in patients who have previously undergone photodynamic therapy.
Fujii
Gildo Y
GY
Doheny Retina Institute at the Doheny Eye Center, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA.
de Juan
Eugene
E
Humayun
Mark S
MS
Chang
Tom S
TS
D000368:Aged; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008266:Macula Lutea / Q000637:transplantation*; D008268:Macular Degeneration / Q000150:complications; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012189:Retrospective Studies; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin